Clinical trials: Stage 1 Hypertension
Hypertension
A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers
To evaluate the safety and pharmacokinetic characteristics of AJU-C52L in healthy adults
- Trial name
- NCT05077475
- Testing
- C52R1H Tab. and C52R2 Tab., AJU-C52L
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Pulmonary Arterial Hypertension
A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of RVT-1201 in patients with…
- Trial name
- NCT03924154
- Testing
- RVT-1201
- Where
- 23 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Altavant Sciences GmbH
Essential Hypertension
A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers
The purpose of this clinical study is to evaluate the pharmacokinetic, pharmacodynamic characteristics and the safety after administration by doses of "BR1400-1", "BR1400-2", "BR1400-3" in healthy volunteers
- Trial name
- NCT06889064
- Testing
- BR1400-1, BR1400-2, BR1400-3
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.
- Trial name
- NCT00281593
- Testing
- Telmisartan, Ramipril
- Where
- 119 sites in United States, Argentina and 4 more
- Volunteers
- 1,354 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models.
- Trial name
- NCT02587325
- Testing
- nab-sirolimus
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
Hypertension
A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet
This is a phase 1, randomized, open-label, crossover study to evaluate the food-effect of single oral dose of TAK-536TCH final formulation tablet in healthy adult male participants.
- Trial name
- NCT02348658
- Testing
- TAK-536TCH
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Takeda
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects
This is a four-part study of the safety, tolerability, and PK profile of sodium nitrite inhalation solution (AIR001) of ascending multiple doses (Part A) and of escalating doses with steady-state sildenafil (Part B) to healthy…
- Trial name
- NCT01409122
- Testing
- 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Aires Pharmaceuticals, Inc.
Hypertension
Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
The population for this current study will include stage 1 and stage 2 hypertensive patients who are newly diagnosed or didn't have treatment during the last 3 months and patients who are currently treated but uncontrolled on…
- Trial name
- NCT00304226
- Testing
- valsartan, amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,288 people, healthy volunteers welcome
- Sponsor
- Novartis
Open Angle Glaucoma, Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension
- Trial name
- NCT02129673
- Testing
- VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- ViSci Ltd.
Uncontrolled Stage 2 Hypertension
REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /
This is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System in subjects with uncontrolled stage 2 hypertension in order to assess the safety and effectiveness…
- Trial name
- REDUCED (NCT05372679)
- Testing
- Renal denervation
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- SoniVie Inc.
Stage 1 Hypertension
Bioactive Milk Peptides and Blood Pressure
The purpose of this study is to investigate the effects of bioactive milk peptides on blood pressure in mildly hypertensive subjects.
- Trial name
- NCT01031485
- Testing
- Milk peptides and plant sterols
- Where
- Finland
- Sponsor
- Valio Ltd
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the…
- Trial name
- A DUE (NCT03904693)
- Testing
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 187 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Ubenimex is being developed for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) to improve exercise capacity and delay clinical worsening.
- Trial name
- LIBERTY2 (NCT02736149)
- Testing
- ubenimex
- Where
- 28 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Eiger BioPharmaceuticals
Hypertension
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
- Trial name
- NCT00695955
- Testing
- Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
- Where
- 41 sites in United States, Chile and 1 more
- Volunteers
- 669 people
- Sponsor
- Takeda
High Blood Pressure
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
This is an open-label, not controlled, sequential, dose escalation study of 16 weeks' duration. The study is composed of two periods: a 0-2 week optional wash-out period depending on previous antihypertensive treatment(s)…
- Trial name
- ANDROMEDA (NCT01056731)
- Testing
- Aliskiren and HCTZ
- Where
- 7 sites in Venezuela
- Volunteers
- 253 people
- Sponsor
- Novartis
Hypertension
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
Essential hypertension is a widespread disease which affects one out of every three adults in the industrialized world. It contributes to cardiovascular disease development, a major and well established risk factor.
- Trial name
- NCT00351130
- Testing
- valsartan, amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis
Hypertension
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline.
- Trial name
- NCT00624065
- Testing
- carvedilol controlled release/lisinopril
- Where
- 76 sites in United States
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Pediatric Hypertension With or Without CKD
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
- Trial name
- NCT01617681
- Testing
- VAL489
- Where
- 27 sites in Belgium, Brazil and 7 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers
The purpose of this clinical study is to evaluate the pharmacokinetics and the safety after administration of BR1018 and coadministration of BR1018A and BR1018B in healthy volunteers
- Trial name
- NCT06889012
- Testing
- BR1018, BR1018A, BR1018B
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Coronary Artery Disease
The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease
This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery…
- Trial name
- NCT00673075
- Testing
- Nebivolol, Carvedilol
- Where
- 34 sites in United States
- Volunteers
- 39 people
- Sponsor
- Forest Laboratories